Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
CYTOF Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: September 19, 2025
Report Source: 2025 2nd Quarter Report
Altamira Therapeutics Ltd. Stock Analysis CYTOF
United States Health Care Nano Cap Report: Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The company employs 13 full-time employees The company went IPO on 2014-08-06. The firm has over two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. Its delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. AM-401, the drug product is based on its OligoPhore technology.
Read More Altamira Therapeutics Ltd (CYTOF) Chart
Key Statistics of Altamira Therapeutics Ltd (CYTOF)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.06Volume
745.00P/E Ratio (TTM)
-52 Week Range
Market Cap
641.73KAvg. Volume
8210.00Dividend Yield
-Financial Metrics & Statements of Altamira Therapeutics Ltd (CYTOF)
FAQ's for Altamira Therapeutics Ltd (CYTOF)
- According to Musaffa’s Shariah screening methodology, Altamira Therapeutics Ltd (CYTOF) is currently classified as NOT HALAL as of September 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Altamira Therapeutics Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Altamira Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Altamira Therapeutics Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Altamira Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Altamira Therapeutics Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.